
MCK AI Price Prediction
Track MCK's AI-powered predictions, market trends, and investment insights.
You don't hold MCK in your mock portfolio yet.
Track MCK's AI-powered predictions, market trends, and investment insights.
You don't hold MCK in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedWith EPS of 38.40 and a PE ratio of 20.20, McKesson’s valuation is consistent with a mature, profitable healthcare distributor rather than a speculative growth story. The earnings profile implies solid, recurring cash flows and a business that is executing well operationally. Profitability appears robust relative to sector norms, supporting a constructive view on the company’s underlying fundamentals.
The stock has risen 7.0% over the last month but still trades below its 200-day moving average of $819.23, indicating a recent rebound within a longer-term consolidation or mild downtrend. Trading at $775.66 with a mid‑range PE, the shares do not appear excessively stretched but also are not clearly in a confirmed uptrend. Technicals suggest a cautious stance until the price can sustain a move back above the 200-day moving average.
Alternative data show a stable to improving operating backdrop: job openings are up 8.5% month over month, signaling expansion or investment in capacity, and LinkedIn followers are growing modestly, reflecting sustained corporate visibility and employer brand strength. Web traffic is high, consistent with McKesson’s scale and ongoing customer engagement, while social media followings are stable to slightly up, suggesting no deterioration in external interest. Overall, these signals tilt modestly positive for business momentum.
McKesson’s fundamentals, as reflected in solid EPS and a reasonable PE, lean bullish, while technicals remain mixed with the stock trading below its 200-day moving average despite a recent rebound. Alternative data, including rising job postings and stable-to-growing digital and social presence, support a constructive view on business momentum. Overall, the balance of evidence points to a neutral stance on the stock near term, with a slight positive bias contingent on confirmation of a renewed uptrend.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
McKesson Corporation (MCK) is currently trading at $784.05 on the NYSE, reflecting a modest 0.4% decline in the latest session. With a market capitalization of $94.2B, McKesson remains one of the largest players in U.S. pharmaceutical distribution, operating across four segments including U.S. Pharmaceutical, Medical-Surgical Solutions, and Prescription Technology Solutions. Daily volume stands at 474,008 shares, suggesting measured institutional participation. The stock's scale and diversified healthcare services footprint continue to underpin its position as a bellwether in the Medical Distribution sector heading into 2026.
TrendEdge's AI model assigns MCK a score of 5 out of 10, placing it in neutral territory. This mid-range score reflects a balance between McKesson's durable business fundamentals — including its dominant pharmaceutical distribution infrastructure and specialty oncology services — and the absence of strong near-term momentum signals. Social sentiment data is currently limited, with only one Reddit mention tracked over the past seven days, offering insufficient crowd sentiment to move the needle. The AI score suggests neither a clear accumulation signal nor a defensive exit, pointing to a stock in a consolidation phase rather than a directional breakout.
Key catalysts to monitor for MCK in 2026 include oncology segment growth, biosimilar distribution volumes, and any regulatory shifts affecting pharmaceutical supply chains. With 588 active job postings, McKesson appears to be sustaining operational investment, which could signal ongoing business expansion. Risks include drug pricing policy headwinds, margin compression in distribution, and potential disruption from vertically integrated health systems. Investors should watch quarterly earnings guidance for updates on the RxTS and International segments as potential re-rating triggers.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
3,776,823
Twitter Followers
21,660
Instagram Followers
11,498
LinkedIn Followers
597,177
Job Postings
608
LinkedIn Employees
24,890
News Mentions
0
Key Metrics